Giammò Alessandro, Geretto Paolo, Ammirati Enrico, Manassero Alberto, Squintone Luisella, Falcone Marco, Costantini Elisabetta, Del Popolo Giulio, Finazzi Agrò Enrico, Giannantoni Antonella, Li Marzi Vincenzo, Mancini Vito, Musco Stefania, Pastorello Mauro, Pistolesi Donatella, Risi Oreste, Gontero Paolo
Struttura Complessa di Neuro-Urologia, Città della Salute e della Scienza, Presidio CTO-USU, 10126 Torino, Italy.
Clinica Urologica, Università di Perugia, 06123 Perugia, Italy.
J Clin Med. 2022 Mar 12;11(6):1569. doi: 10.3390/jcm11061569.
The aim of the present study is to analyze the outcomes of urethral bulking in the treatment of non-neurogenic female stress and mixed urinary incontinence and to assess predictors of clinical outcomes. We retrospectively included all consecutive patients affected by stress or mixed urinary incontinence and treated with urethral bulking. Outcomes were evaluated via the PGI-I questionnaire and the 24-h pad test. Between January 2010 and January 2020, we treated 216 patients (Bulkamid n = 206; Macro-plastique n = 10). The median age at surgery was 66 years (IQR 55−73.75). The median follow-up was 12 months (IQR 12−24). In total, 23.8% of patients were subjected to prior incontinence surgery, 63.8% of patients were affected by genuine stress urinary incontinence, 36.2% reported mixed urinary incontinence, whereas detrusor overactivity was confirmed in only 24.9%. The dry rate was 32.9%; nevertheless, 69.9% of patients declared themselves “very improved” or “improved” (PGI-I1-2). Low complications were observed, mostly classified as Clavien I. After univariate and multivariate analyses, the only statistically significant independent predictor of “dry” outcome was the 24 h pad test, p < 0.001. Urethral bulking could be proposed with more expectations of success in patients with mild urinary incontinence. Patients affected by moderate−severe incontinence are less likely to obtain clinical success; therefore, they should be carefully counselled about clinical expectations before the procedure.
本研究的目的是分析尿道填充术治疗非神经源性女性压力性尿失禁和混合性尿失禁的疗效,并评估临床疗效的预测因素。我们回顾性纳入了所有连续的压力性或混合性尿失禁患者,并接受了尿道填充术治疗。通过PGI-I问卷和24小时尿垫试验评估疗效。在2010年1月至2020年1月期间,我们治疗了216例患者(Bulkamid组n = 206;Macro-plastique组n = 10)。手术时的中位年龄为66岁(四分位间距55-73.75)。中位随访时间为12个月(四分位间距12-24)。总共23.8%的患者曾接受过尿失禁手术,63.8%的患者患有真性压力性尿失禁,36.2%的患者报告有混合性尿失禁,而仅24.9%的患者证实存在逼尿肌过度活动。干爽率为32.9%;然而,69.9%的患者表示自己“非常改善”或“改善”(PGI-I 1-2)。观察到的并发症较少,大多分类为Clavien I级。经过单因素和多因素分析,“干爽”结局的唯一具有统计学意义的独立预测因素是24小时尿垫试验,p < 0.001。对于轻度尿失禁患者,尿道填充术有望取得更多成功。中重度尿失禁患者获得临床成功的可能性较小;因此,在手术前应仔细向他们咨询临床预期。